Clinical Trials on Stage III Solid Tumors in Japan

Total 263 results

City of Hope Medical Center

Recruiting

Stomach Cancer Exosome-based Detection (DESTINEX)

Gastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditions

United States, Japan
Incyte Biosciences Japan GK

Completed

A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Japan
Kyowa Kirin Co., Ltd.

Completed

A Study of LY2523355 in Patients With Solid Cancer (2523355-001)

Solid Tumors

Japan
AstraZeneca

Completed

Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
Eli Lilly and Company

Completed

A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors

Solid Tumors

Japan
Incyte Biosciences Japan GK

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550

Solid Tumors

Japan
AbbVie (prior sponsor, Abbott)

Completed

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Solid Tumors

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KRN951 in Patients With Solid Tumors

Solid Tumors

Japan
Eisai Inc.

Completed

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

Cancer: Solid Tumors

Japan
GlaxoSmithKline

Completed

Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)

Solid Tumours

Japan
AstraZeneca

Terminated

Safety and Tolerability Study of AZD7762 in Combination With Gemcitabine

Cancer | Solid Tumors | Advanced Solid Malignancies

Japan
Merck KGaA, Darmstadt, Germany

Completed

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Solid Tumors

Japan
Shiga University
Tokyo University

Completed

Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors

Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor

Advanced Solid Tumors

Japan
Eli Lilly and Company
Parexel

Completed

Study of IMC-1121B in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Takara Bio Inc.

Completed

A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma

Melanoma Stage IV | Melanoma Stage III

Japan
Genta Incorporated

Unknown

Study of Tesetaxel in Japanese Patients With Solid Tumors

Advanced Solid Tumors

Japan
Eisai Co., Ltd.

Completed

A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors

Solid Tumors

Japan
Bristol-Myers Squibb

Completed

A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of DS-1123a in Advanced Solid Tumours

Advanced Solid Malignant Tumors

Japan
Daiichi Sankyo Co., Ltd.

Terminated

Open Label Study of DS-5573a

Advanced Solid Malignant Tumors

Japan
Novartis Pharmaceuticals

Completed

A Dose Escalation of Gimatecan Administered Orally to Japanese Patients With Advanced Solid Tumor.

Advanced Solid Tumors

Japan
Novartis

Completed

A Phase I Dose Escalation Study of LBQ707 (Gimatecan) Administered Orally Twice Per Week to Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
AstraZeneca

Active, not recruiting

MEDI5752 in Japanese Patients With Advanced Solid Tumors.

Advanced Solid Tumors

Japan
Takeda

Completed

A Study of Niraparib as Single Agent in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Ono Pharmaceutical Co. Ltd

Completed

Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

Phase I Dose Escalating Study of TKI258

Advanced Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors

Solid Tumors

Japan
Novartis Pharmaceuticals

Terminated

Dose Escalation of HSP990 in Japan/Korea

Advanced Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Safety And Tolerability, Solid Tumor

Advanced Malignant Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Advanced Malignant Solid Tumors

Japan
Astellas Pharma Inc

Completed

Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Puma Biotechnology, Inc.

Completed

A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Advanced Malignant Solid Tumors

Japan
Novartis Pharmaceuticals

Terminated

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

Cancer | Solid Tumor | Advanced Solid Tumor

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Hokkaido Pancreatobiliary Endoscopic Intervention...
Hokkaido University Hospital

Completed

EUS-FNA for Patients With Antithrombotic Agents

Solid Tumor

Japan
Novartis Pharmaceuticals

Completed

A Phase I Study of LEE011 in Asian Patients

Advanced Solid Tumors

Japan
Sanofi

Completed

A Dose-escalation Study of Ombrabulin in Combination With Paclitaxel and Carboplatin in Patients With Advanced Solid Tumors

Advanced Solid Tumors

Japan
Sanofi

Completed

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Advance Solid Tumors

Japan
Daiichi Sankyo Co., Ltd.

Completed

Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Advanced Solid Malignant Tumors

Japan
3D Medicines (Sichuan) Co., Ltd.

Completed

A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

Japan
AstraZeneca

Completed

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Advanced Solid Tumor | Advanced Solid Malignancy

Japan
Takeda

Active, not recruiting

A Study of TAK-103 in Adult With Solid Tumors

Solid Tumors

Japan
Takeda

Active, not recruiting

A Study of TAK-102 in Adult With Previously-Treated Solid Tumors

Solid Tumors

Japan
Novartis Pharmaceuticals

Completed

Dose Escalation Study of AUY922 in Advanced Solid Malignancies in Japan

Advanced Solid Tumors

Japan
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
Genmab
BioNTech SE

Recruiting

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Malignant Solid Tumor

Japan
Genmab
BioNTech SE

Active, not recruiting

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Solid Tumor

Japan
AstraZeneca

Completed

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

Advanced Solid Tumor

Japan
Ono Pharmaceutical Co. Ltd

Completed

ONO-7913 Phase I Study (ONO-7913)

Solid Tumor

Japan

3

Subscribe